POST Online Media Lite Edition



 

Pfizer to acquire Hospira, total enterprise value $17 billion

Staff writer |
Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion. The boards of both companies have unanimously approved the merger, which is expected to be immediately accretive upon closing.

Article continues below






The merger is expected to be accretive by $0.10 - $0.12 per share for the first full year following the close of the transaction with additional accretion anticipated thereafter.

Both sterile injectables and biosimilars are large and growing categories. The global marketplace value for generic sterile injectables is estimated to be $70 billion in 2020. The global marketplace for biosimilars is estimated to be approximately $20 billion in 2020.

Pfizer expects to finance the transaction through a combination of existing cash and new debt, with approximately two-thirds of the value financed from cash and one-third from debt. In addition, Pfizer anticipates the transaction to deliver $800 million in annual cost savings by 2018.

The transaction is subject to customary closing conditions, including regulatory approvals in several jurisdictions and approval of Hospira's shareholders, and is expected to close in the second half of 2015.

This strategically complementary combination will add a groing revenue stream and a platform for growth for Pfizer's GEP business.

The expanded portfolio of sterile injectable pharmaceuticals, composed of Hospira's broad generic sterile injectables product line, including acute care and oncology injectables, with a number of differentiated presentations, as well as its biosimilars portfolio, combined with GEP's branded sterile injectables, including anti-infectives, anti-inflammatories and cytotoxics, will create a leading global sterile injectables business.

The combination also reinforces GEP's growth strategy to build a broad portfolio of biosimilars in Pfizer's therapeutic areas of strength through the addition of Hospira's portfolio that includes several marketed biosimilars. Pfizer will also use its existing commercial capabilities, global scale, scientific expertise and world class development capabilities to significantly expand the reach of Hospira's products, which are currently distributed primarily in the United States, to Europe and key emerging markets, where GEP has a significant presence.


What to read next

Pfizer completes Hospira acquisition
Hospira shareholders approve $17 billion merger with Pfizer
Pfizer offers concessions to win approval for $15bn Hospira takeover